Cytokinetics Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team.
Our next presenting company is Cytokinetics. And speaking on behalf of the company, we have CEO, Robert Blum. Before I turn it over to Robert, I just wanted to highlight that there is a Q&A for those listening on the webcast. And if you get your question in there, I'm happy to kind of squeeze it in there on your behalf.
So with that, Robert, over to you.
Thank you, and thank you to JPMorgan for inviting Cytokinetics to be presenting an update here at the 2023 conference. I'm very pleased to be speaking on behalf of Cytokinetics. This is a very important year. I'll be making some forward-looking statements. I'll draw reference to the SEC filings for caveats on those statements,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |